At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 247 enrolled
Drug / intervention
Teneligliptin 20mg +2 moredrug
Likely dose
Teneligliptin 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Teneligliptin 20mg, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 247 participants across 1 site.
Detailed Summary
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with metformin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedOct 2016
Primary CompletionSep 2018
TodayJul 2026
First PostedOct 5, 2016
Enrollment StartSep 1, 2016
Primary CompletionSep 25, 2018
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.7 years ago
Interventions
Teneligliptin 20mgdrug
Placebodrug
Metformin ≥ 1000 mgdrug